China halts Sun Pharma rivastigmine sales
The order creates a regulatory prohibition on importing, distributing, and administering that rivastigmine formulation in China, removing it from Chinese pharmaceutical supply and clinical use channels.
Change
On January 26, 2026, China's National Medical Products Administration ordered a halt to the import, sale, and use of Sun Pharmaceutical Industries' rivastigmine hydrogen tartrate capsules.
Why it matters
A remote inspection identified shortcomings in the company's production processes, including failures in contamination prevention and in the quality management department’s fulfillment of duties. The regulator's action covers rivastigmine hydrogen tartrate capsules and prohibits their importation, commercial sale, and clinical use within China. The ban was posted on January 26, 2026. Sun Pharmaceutical Industries did not provide a comment when contacted.
Implications
- — Importers and customs agents in China must stop bringing Sun Pharma's rivastigmine hydrogen tartrate capsules into the country.
- — Distributors, pharmacies, and hospitals in China must cease selling and supplying that specific rivastigmine formulation.
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer